VEGFA and breast cancer: Our findings that MVs shed by breast cancer cells are insensitive to Bevacizumab at the levels used in functional assays and in therapeutic applications, offer an additional mechanism that might account for some of the ineffectiveness of this VEGF antibody in cancer treatment.